Compare Wockhardt with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs CIPLA - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT CIPLA WOCKHARDT/
CIPLA
 
P/E (TTM) x -23.6 24.1 - View Chart
P/BV x 1.2 2.5 50.6% View Chart
Dividend Yield % 0.0 0.7 0.5%  

Financials

 WOCKHARDT   CIPLA
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
CIPLA
Mar-19
WOCKHARDT/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,012678 149.3%   
Low Rs532484 109.9%   
Sales per share (Unadj.) Rs355.9198.2 179.5%  
Earnings per share (Unadj.) Rs-60.318.5 -325.4%  
Cash flow per share (Unadj.) Rs-46.835.0 -133.7%  
Dividends per share (Unadj.) Rs0.013.00 0.3%  
Dividend yield (eoy) %00.5 0.3%  
Book value per share (Unadj.) Rs257.8186.3 138.4%  
Shares outstanding (eoy) m110.63805.70 13.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.9 74.0%   
Avg P/E ratio x-12.831.4 -40.8%  
P/CF ratio (eoy) x-16.516.6 -99.4%  
Price / Book Value ratio x3.03.1 96.0%  
Dividend payout %016.2 -0.1%   
Avg Mkt Cap Rs m85,379468,031 18.2%   
No. of employees `0006.322.6 27.6%   
Total wages/salary Rs m9,37128,565 32.8%   
Avg. sales/employee Rs Th6,295.07,053.1 89.3%   
Avg. wages/employee Rs Th1,498.31,261.5 118.8%   
Avg. net profit/employee Rs Th-1,066.3659.1 -161.8%   
INCOME DATA
Net Sales Rs m39,369159,710 24.7%  
Other income Rs m1,2024,766 25.2%   
Total revenues Rs m40,571164,475 24.7%   
Gross profit Rs m1830,973 0.1%  
Depreciation Rs m1,49513,263 11.3%   
Interest Rs m2,5551,684 151.7%   
Profit before tax Rs m-2,83020,791 -13.6%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m2575,695 4.5%   
Profit after tax Rs m-6,66914,924 -44.7%  
Gross profit margin %019.4 0.2%  
Effective tax rate %-9.127.4 -33.2%   
Net profit margin %-16.99.3 -181.3%  
BALANCE SHEET DATA
Current assets Rs m33,796124,266 27.2%   
Current liabilities Rs m26,91737,715 71.4%   
Net working cap to sales %17.554.2 32.2%  
Current ratio x1.33.3 38.1%  
Inventory Days Days7991 87.6%  
Debtors Days Days8995 94.1%  
Net fixed assets Rs m39,664105,190 37.7%   
Share capital Rs m5531,611 34.3%   
"Free" reserves Rs m27,968148,511 18.8%   
Net worth Rs m28,522150,123 19.0%   
Long term debt Rs m21,73138,301 56.7%   
Total assets Rs m81,620239,633 34.1%  
Interest coverage x-0.113.3 -0.8%   
Debt to equity ratio x0.80.3 298.6%  
Sales to assets ratio x0.50.7 72.4%   
Return on assets %-5.06.9 -72.7%  
Return on equity %-23.49.9 -235.2%  
Return on capital %-7.711.8 -64.8%  
Exports to sales %034.7 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA55,419 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80757,410 17.1%   
Fx outflow Rs m1,78919,041 9.4%   
Net fx Rs m8,01938,368 20.9%   
CASH FLOW
From Operations Rs m68416,911 4.0%  
From Investments Rs m6,302-16,687 -37.8%  
From Financial Activity Rs m-7,695-3,487 220.7%  
Net Cashflow Rs m-664-3,451 19.2%  

Share Holding

Indian Promoters % 74.5 16.0 465.6%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 2.3 12.2 18.9%  
FIIs % 7.7 23.7 32.5%  
ADR/GDR % 0.1 1.1 9.1%  
Free float % 15.4 26.2 58.8%  
Shareholders   67,757 161,166 42.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare WOCKHARDT With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Rising Petrol and Diesel Prices, DHFL Saga, and Top Cues in Focus Today(Pre-Open)

Indian share markets ended their trading session marginally higher yesterday. On the sectoral front, gains were seen in the metal sector and realty sector.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Sep 18, 2019 (Close)

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT - AJANTA PHARMA COMPARISON

COMPARE WOCKHARDT WITH

MARKET STATS